Analysts Issue Forecasts for OS Therapies Q2 Earnings

OS Therapies Incorporated (NYSEAMERICAN:OSTX) – Brookline Capital Markets lowered their Q2 2026 earnings per share (EPS) estimates for OS Therapies in a research note issued on Monday, June 8th. Brookline Capital Markets analyst K. Raja now anticipates that the company will earn ($0.23) per share for the quarter, down from their prior forecast of ($0.19). The consensus estimate for OS Therapies’ current full-year earnings is $0.16 per share. Brookline Capital Markets also issued estimates for OS Therapies’ Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at $0.09 EPS and FY2030 earnings at $0.15 EPS.

OS Therapies (NYSEAMERICAN:OSTX) last announced its quarterly earnings results on Monday, May 18th. The company reported ($0.27) earnings per share (EPS) for the quarter.

OSTX has been the subject of a number of other reports. Lake Street Capital reduced their target price on shares of OS Therapies from $14.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 4th. Finally, D. Boral Capital reiterated a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a research note on Thursday, April 30th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, OS Therapies has a consensus rating of “Moderate Buy” and an average price target of $16.50.

OS Therapies Price Performance

Shares of OSTX stock opened at $1.74 on Wednesday. OS Therapies has a 1-year low of $1.15 and a 1-year high of $2.57. The stock’s 50-day moving average is $1.62 and its 200 day moving average is $1.55. The company has a market cap of $77.50 million, a P/E ratio of -1.61 and a beta of -0.95.

Institutional Investors Weigh In On OS Therapies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC purchased a new stake in shares of OS Therapies during the third quarter worth about $183,000. Two Sigma Investments LP acquired a new stake in OS Therapies in the 3rd quarter worth approximately $169,000. Geode Capital Management LLC boosted its stake in OS Therapies by 31.1% in the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after purchasing an additional 58,350 shares in the last quarter. Virtu Financial LLC grew its position in OS Therapies by 252.0% during the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock worth $149,000 after purchasing an additional 54,269 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in OS Therapies during the 2nd quarter worth approximately $63,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.